T-Cypher Bio

📍 Oxford, United Kingdom🗓 Founded 2021👥 35 employees💰 Last funded Jan 2021
Biotechnology Research🌐 tcypherbio.com
Website LinkedIn
At T-Cypher Bio we generate novel TCR-based therapeutics that have the potential to transform the treatment of immune-mediated disease. Our proprietary platforms provide unique insight into T cell based immunity in both health and disease. High throughput, high-resolution profiling of the immune synapse enables us to map the intracellular target space and profile T cell specificity. These platforms not only give us tools to build highly innovative drugs, but also build immune system data sets of unprecedented size. These data sets support cutting edge computational modelling of T cell repertoires which will revolutionize T cell immunology. To build our oncology pipeline, we validate novel, shared, tumour-specific targets and identify panels of rare functionally-defined T cell clones. The unique TCRs we identify are the foundation of our broad pipeline of lifesaving therapeutics for underserved solid tumour patients.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in T-Cypher Bio?
T-Cypher Bio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did T-Cypher Bio last raise funding?
The most recent investment in T-Cypher Bio recorded on gritt.io was in January 2021.
When was T-Cypher Bio founded?
T-Cypher Bio was founded in 2021.
What industry is T-Cypher Bio in?
T-Cypher Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is T-Cypher Bio based?
T-Cypher Bio is headquartered in Oxford, United Kingdom.